The stock of AngioDynamics, Inc. (NASDAQ:ANGO) is a huge mover today! About 556,316 shares traded hands or 278.25% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 58.42% since March 2, 2016 and is uptrending. It has outperformed by 50.17% the S&P500.
The move comes after 8 months negative chart setup for the $601.59M company. It was reported on Oct, 5 by Barchart.com. We have $15.76 PT which if reached, will make NASDAQ:ANGO worth $30.08M less.
Analysts await AngioDynamics, Inc. (NASDAQ:ANGO) to report earnings on October, 13. They expect $0.13 earnings per share, up 18.18% or $0.02 from last year’s $0.11 per share. ANGO’s profit will be $4.71 million for 31.90 P/E if the $0.13 EPS becomes a reality. After $0.19 actual earnings per share reported by AngioDynamics, Inc. for the previous quarter, Wall Street now forecasts -31.58% negative EPS growth.
AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage
Out of 5 analysts covering AngioDynamics (NASDAQ:ANGO), 1 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 20% are positive. AngioDynamics has been the topic of 7 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The rating was upgraded by Zacks to “Sell” on Monday, August 31. The firm has “Neutral” rating given on Wednesday, September 23 by Sidoti. The firm has “Mkt Perform” rating given on Tuesday, November 10 by Raymond James. The stock has “Hold” rating given by Canaccord Genuity on Tuesday, April 5. The rating was reinitiated by Piper Jaffray with “Neutral” on Friday, April 8. The company was maintained on Friday, January 8 by Canaccord Genuity. The company was initiated on Friday, July 24 by KeyBanc Capital Markets.
According to Zacks Investment Research, “AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company’s diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products.”
Insitutional Activity: The institutional sentiment increased to 1.87 in 2016 Q2. Its up 0.50, from 1.37 in 2016Q1. The ratio increased, as 11 funds sold all AngioDynamics, Inc. shares owned while 20 reduced positions. 10 funds bought stakes while 48 increased positions. They now own 24.22 million shares or 1.02% less from 24.47 million shares in 2016Q1.
California Public Employees Retirement System last reported 0% of its portfolio in the stock. Public Sector Pension Board has 18,124 shares for 0% of their US portfolio. Gotham Asset Management Ltd Llc last reported 14,848 shares in the company. Spark Invest Management Limited Liability Corp has 0.13% invested in the company for 95,900 shares. D E Shaw Comm has 107,982 shares for 0% of their US portfolio. Ledyard National Bank holds 1,500 shares or 0% of its portfolio. Tiaa Cref Inv Limited Com has invested 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Ls Limited Com last reported 1,108 shares in the company. Voya Management Ltd Com last reported 0% of its portfolio in the stock. The Illinois-based Ubs Asset Mgmt Americas has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). The Iowa-based Principal Fincl Grp Inc Inc has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Goldman Sachs reported 29,281 shares or 0% of all its holdings. Teachers Retirement Sys Of The State Of Kentucky last reported 0% of its portfolio in the stock. Perkins Cap Management accumulated 44,850 shares or 0.74% of the stock. Teacher Retirement Of Texas last reported 0% of its portfolio in the stock.
Insider Transactions: Since April 21, 2016, the stock had 0 insider buys, and 4 insider sales for $65.86 million net activity. Shares for $32.76M were sold by Avista Capital Partners GP – LLC on Friday, August 5. Trowbridge Stephen A sold $159,184 worth of stock or 12,940 shares. Burgstahler David F had sold 2.25 million shares worth $32.90 million on Friday, August 5. Greiner Charles R sold $43,183 worth of stock.
More recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: Nasdaq.com which released: “Earnings Reaction History: AngioDynamics Inc., 75.0% Follow-Through Indicator …” on October 05, 2016. Also Blogs.Wsj.com published the news titled: “Stocks to Watch: Eli Lilly, AngioDynamics, AZZ” on October 05, 2016. Globenewswire.com‘s news article titled: “AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer” with publication date: July 25, 2016 was also an interesting one.
ANGO Company Profile
AngioDynamics, Inc., incorporated on July 30, 1992, designs, makes and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.